Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Avillion, Pearl Therapeutics Sign Clinical Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Avillion, Pearl Therapeutics Sign Clinical Agreement

To advance PT027 through a global clinical development program for the treatment of asthma

By: Betsy Louda

, Contract Pharma

Avillion has signed a clinical co-development agreement with Pearl Therapeutics Inc., a wholly owned subsidiary of AstraZeneca, to advance PT027 through a global clinical development program for the treatment of asthma.

 

PT027 is an investigational fixed dose combination of budesonide (an inhaled corticosteroid) and albuterol (a short-acting beta-2 agonist). Avillion will be responsible for developing PT027 through an extensive clinical development programme and will finance the programme through to regulatory approval. 

 

Allison Jeynes-Ellis, MD, chief executive officer of Avillion, said, “This new collaboration is another great example of how our innovative clinical development model and exceptional operational capabilities can be used to bolster the productivity of our partners’ development pipeline. We have already demonstrated the success of our approach in our partnerships with Pfizer and Merck KGaA. We are looking forward to initiating this exciting clinical development program for PT027 in asthma.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics